docruДоктор.РуTitle1727-23782713-2994ООО "ГК "РУСМЕДИКАЛ"10.31550/1727-2378-2023-22-5-40-48docru-190Research ArticleГИНЕКОЛОГИЯGYNECOLOGYМенопаузальный переход — фокус на раннее и эффективное снижение кардиометаболических рисковMenopausal Transition — Time for Early and Effective Targeting of Cardiometabolic Riskshttps://orcid.org/0000-0003-2864-066XЮреневаС. В.YurenevaS. V.

Светлана Владимировна Юренева, д. м. н., профессор, заместитель директора по научной работе, профессор

Институт онкогинекологии и маммологии; кафедра акушерства и гинекологии

117997; ул. Академика Опарина, д. 4; Москва

117997; 4 Academician Oparin Str.; Moscow

syureneva@gmail.comhttps://orcid.org/0000-0002-8160-5612ОрловаЯ. А.OrlovaYa. A.

Яна Артуровна Орлова, д. м. н., профессор, заведующая отделом, заведующая кафедрой

Медицинский научно-образовательный центр; отдел возраст-ассоциированных заболеваний; факультет фундаментальной медицины; кафедра терапии

119991; Ленинские горы, д. 1; Москва

119991; 1 Leninskiye Gory; Moscow

5163002@bk.ruФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава РоссииРоссияV.I. Kulakov National Medical Scientific Centre of Obstetrics, Gynecology and Perinatal MedicineRussian FederationФГБОУ ВО «Московский государственный университет имени М.В. Ломоносова»РоссияLomonosov Moscow State UniversityRussian Federation202318022025225ГИНЕКОЛОГИЯ4048Copyright © Юренева С.В., Орлова Я.А., 20252025Юренева С.В., Орлова Я.А.Yureneva S.V., Orlova Y.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://docru.elpub.ru/jour/article/view/190   Цель обзора

   Цель обзора: рассмотреть особенности факторов риска и частоту встречаемости сердечно-сосудистых заболеваний у женщин среднего зрелого возраста с фокусированием на период менопаузального перехода, который имеет ключевое значение для проведения ранней профилактики.

   Основные положения

   Основные положения. Исследования показали четкие паттерны неблагоприятных изменений в распределении жировой ткани, липидного профиля, структурных и функциональных показателей сосудистого здоровья в течение менопаузального перехода независимо от этапа старения женщины.

   Заключение

   Заключение. Кардиометаболическое здоровье женщин среднего возраста систематически недооценивается, период менопаузального перехода может быть критическим окном возможностей для начала ранних превентивных вмешательств на основе междисциплинарного подхода и назначения менопаузальной гормональной терапии.

   Aim

   Aim: to examine the features of risk factors and cardiovascular diseases in middle-aged women with a focus on period of the menopausal transition, which is of key importance to early prevention.

   Key Points

   Key Points. The studies showed distinct patterns of adverse changes in fat distribution, lipid profile, structural and functional indicators of vascular health during the menopausal transition regardless of aging.

   Conclusion

   Conclusion. The cardiometabolic health of middle-aged women is systematically underestimated; the period of menopausal transition may be a critical window of opportunity for initiation of early preventive interventions based on a multidisciplinary approach and menopausal hormone therapy.

здоровое старениеменопаузаменопаузальный переходсердечно-сосудистые рискипревентивные стратегиименопаузальная гормональная терапияhealthy agingmenopausemenopause transitioncardiovascular riskspreventive strategiesmenopausal hormone therapyАвторы заявляют об отсутствии внешнего финансирования при проведении исследования и написании статьиThe authors declare that there is no external funding for the exploration and analysis workReferencesDeVito L.M., Barzilai N., Cuervo A.M. et al. Extending human healthspan and longevity : a symposium report. Ann. N. Y. Acad. Sci. 2022;1507(1):70–83. DOI: 10.1111/nyas.1468DeVito L.M., Barzilai N., Cuervo A.M. et al. Extending human healthspan and longevity : a symposium report. Ann. N. Y. Acad. Sci. 2022;1507(1):70–83. DOI: 10.1111/nyas.1468Maas A.H.E.M., Rosano G., Cifkova R. et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur. Heart J. 2021;42:967–984. DOI: 10.1093/eurheartj/ehaa1044Maas A.H.E.M., Rosano G., Cifkova R. et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur. Heart J. 2021;42:967–984. DOI: 10.1093/eurheartj/ehaa1044El Khoudary S.R., Aggarwal B., Beckie T.M. et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020(25);142:e506–e532. DOI: 10.1161/CIR.0000000000000912El Khoudary S.R., Aggarwal B., Beckie T.M. et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020(25);142:e506–e532. DOI: 10.1161/CIR.0000000000000912Maas A.H.E.M. Maintaining cardiovascular health: an approach specific to women. Maturitas. 2019;124:68–71. DOI: 10.1016/j.maturitas.2019.03.021Maas A.H.E.M. Maintaining cardiovascular health: an approach specific to women. Maturitas. 2019;124:68–71. DOI: 10.1016/j.maturitas.2019.03.021Stuenkel C.A. Do we have new preventive strategies for optimizing cardiovascular health in women? Climacteric. 2019;22(2):133–139. DOI: 10.1080/13697137.2018.1561665Stuenkel C.A. Do we have new preventive strategies for optimizing cardiovascular health in women? Climacteric. 2019;22(2):133–139. DOI: 10.1080/13697137.2018.1561665Cushman M., Shay C., Howard V. et al. Ten-year differences in women’s awareness related to coronary heart disease: results of the 2019 American Heart Association National Survey: a special report from the American Heart Association. Circulation. 2021;143(7):e239–e248. DOI: 10.1161/CIR.0000000000000907Cushman M., Shay C., Howard V. et al. Ten-year differences in women’s awareness related to coronary heart disease: results of the 2019 American Heart Association National Survey: a special report from the American Heart Association. Circulation. 2021;143(7):e239–e248. DOI: 10.1161/CIR.0000000000000907Wenger N.K., Lloyd-Jones D.M., Elkind M.S.V. et al. American Heart Association. Call to action for cardiovascular disease in women: epidemiology, awareness, access, and delivery of equitable health care: a presidential advisory from the American Heart Association. Circulation 2022;145:e1059–e1071. DOI: 10.1161/CIR.0000000000001071Wenger N.K., Lloyd-Jones D.M., Elkind M.S.V. et al. American Heart Association. Call to action for cardiovascular disease in women: epidemiology, awareness, access, and delivery of equitable health care: a presidential advisory from the American Heart Association. Circulation 2022;145:e1059–e1071. DOI: 10.1161/CIR.0000000000001071Bello N.A., Merz C.N.B., Cheng S. A scientific imperative as seen through a sharpened lens: sex, gender, and the cardiovascular condition. Circ. Res. 2022;130:433–435. DOI: 10.1161/CIRCRESAHA.122.320825Bello N.A., Merz C.N.B., Cheng S. A scientific imperative as seen through a sharpened lens: sex, gender, and the cardiovascular condition. Circ. Res. 2022;130:433–435. DOI: 10.1161/CIRCRESAHA.122.320825Luu J.M., Wei J., Shufelt C.L. et al. Clinical Practice Variations in the Management of Ischemia With No Obstructive Coronary Artery Disease. J. Am. Heart Assoc. 2022;11:e022573. DOI: 10.1161/JAHA.121.022573Luu J.M., Wei J., Shufelt C.L. et al. Clinical Practice Variations in the Management of Ischemia With No Obstructive Coronary Artery Disease. J. Am. Heart Assoc. 2022;11:e022573. DOI: 10.1161/JAHA.121.022573Maas A.H.E.M., Bouatia-Naji N., Persu A., Adlam D. Spontaneous coronary artery dissections and fibromuscular dysplasia: Current insights on pathophysiology, sex and gender. Int. J. Cardiol 2019;286:220–225. DOI: 10.1016/j.ijcard.2018.11.023Maas A.H.E.M., Bouatia-Naji N., Persu A., Adlam D. Spontaneous coronary artery dissections and fibromuscular dysplasia: Current insights on pathophysiology, sex and gender. Int. J. Cardiol 2019;286:220–225. DOI: 10.1016/j.ijcard.2018.11.023Ibanez B., James S., Agewa S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2018;39(2):119–177. DOI: 10.1093/eurheartj/ehx393Ibanez B., James S., Agewa S. et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2018;39(2):119–177. DOI: 10.1093/eurheartj/ehx393Shaw L.J., Min J.K., Nasir K. et al. Sex differences in calcified plaque and long-term cardiovascular mortality: observations from the CAC Consortium. Eur. Heart J. 2018;39(41):3727–3735. DOI: 10.1093/eurheartj/ehy534Shaw L.J., Min J.K., Nasir K. et al. Sex differences in calcified plaque and long-term cardiovascular mortality: observations from the CAC Consortium. Eur. Heart J. 2018;39(41):3727–3735. DOI: 10.1093/eurheartj/ehy534Konst R.E., Elias-Smale S.E., Lier A. et al. Different cardiovascular risk factors and psychosocial burden in symptomatic women with and without obstructive coronary artery disease. Eur. J. Prev. Cardiol 2019;26(6):657–659. DOI: 10.1177/2047487318814298Konst R.E., Elias-Smale S.E., Lier A. et al. Different cardiovascular risk factors and psychosocial burden in symptomatic women with and without obstructive coronary artery disease. Eur. J. Prev. Cardiol 2019;26(6):657–659. DOI: 10.1177/2047487318814298Parikh N.I., Gonzalez J.M., Anderson C.A.M. et al. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. Circulation. 2021;143(18):e902–e916. DOI: 10.1161/CIR.0000000000000961Parikh N.I., Gonzalez J.M., Anderson C.A.M. et al. Adverse pregnancy outcomes and cardiovascular disease risk: unique opportunities for cardiovascular disease prevention in women: a scientific statement from the American Heart Association. Circulation. 2021;143(18):e902–e916. DOI: 10.1161/CIR.0000000000000961Visseren F.L.J., Mach F., Smulders Y.M. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2021;42(34):3227–3337. DOI: 10.1093/eurheartj/ehab484Visseren F.L.J., Mach F., Smulders Y.M. et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur. Heart J. 2021;42(34):3227–3337. DOI: 10.1093/eurheartj/ehab484do Couto C.P., Policiano C., Pinto F.J. et al. Endometriosis and cardiovascular disease : A systematic review and meta-analysis. Maturitas. 2023;171:45–52. DOI: 10.1016/j.maturitas.2023.04.001do Couto C.P., Policiano C., Pinto F.J. et al. Endometriosis and cardiovascular disease : A systematic review and meta-analysis. Maturitas. 2023;171:45–52. DOI: 10.1016/j.maturitas.2023.04.001Zhao L., Zhu Z., Lou H. et al. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget. 2016;7(23):33715–33721. DOI: 10.18632/oncotarget.9553;7:33715-21Zhao L., Zhu Z., Lou H. et al. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget. 2016;7(23):33715–33721. DOI: 10.18632/oncotarget.9553;7:33715-21Cho L., Davis M., Elgendy I. et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women : JACC state-of-the-art review. J. Am. Coll. Cardiol 2020;75(20):2602–2618. DOI: 10.1016/j.jacc.2020.03.060Cho L., Davis M., Elgendy I. et al. Summary of updated recommendations for primary prevention of cardiovascular disease in women : JACC state-of-the-art review. J. Am. Coll. Cardiol 2020;75(20):2602–2618. DOI: 10.1016/j.jacc.2020.03.060Lia M., Zhub Y., Weid J. et al. The global prevalence of premature ovarian insufficiency : a systematic review and meta-analysis. Climacteric. 2023;26(2):95–102. DOI: 10.1080/13697137.2022.2153033Lia M., Zhub Y., Weid J. et al. The global prevalence of premature ovarian insufficiency : a systematic review and meta-analysis. Climacteric. 2023;26(2):95–102. DOI: 10.1080/13697137.2022.2153033Santoro N., Roeca C., Peters B.A., Neal-Perry G. The menopause transition: signs, symptoms, and management options. J. Clin. Endocrinol. Metab. 2021;106(1):1–15. DOI: 10.1210/clinem/dgaa764Santoro N., Roeca C., Peters B.A., Neal-Perry G. The menopause transition: signs, symptoms, and management options. J. Clin. Endocrinol. Metab. 2021;106(1):1–15. DOI: 10.1210/clinem/dgaa764Harlow S.D., Gass M., Hall J.E. et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012;15(2):105–114. DOI: 10.3109/13697137.2011.650656Harlow S.D., Gass M., Hall J.E. et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric. 2012;15(2):105–114. DOI: 10.3109/13697137.2011.650656El Khoudary S.R., Greendale G., Crawford S.L. et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. 2019;26(10):1213–1227. DOI: 10.1097/GME.0000000000001424El Khoudary S.R., Greendale G., Crawford S.L. et al. The menopause transition and women’s health at midlife: a progress report from the Study of Women’s Health Across the Nation (SWAN). Menopause. 2019;26(10):1213–1227. DOI: 10.1097/GME.0000000000001424Bacon E.R., Mishra A., Wang Y. et al. Neuroendocrine aging precedes perimenopause and is regulated by DNA methylation. Neurobiol. Aging 2019;74:213–224. DOI: 10.1016/j.neurobiolaging.2018.09.029Bacon E.R., Mishra A., Wang Y. et al. Neuroendocrine aging precedes perimenopause and is regulated by DNA methylation. Neurobiol. Aging 2019;74:213–224. DOI: 10.1016/j.neurobiolaging.2018.09.029Carson M.Y., Thurston R.C. Vasomotor symptoms and their links to cardiovascular disease risk. Curr. Opin. Endocr. Metab. Res 2023;30:100448. DOI: 10.1016/j.coemr.2023.100448Carson M.Y., Thurston R.C. Vasomotor symptoms and their links to cardiovascular disease risk. Curr. Opin. Endocr. Metab. Res 2023;30:100448. DOI: 10.1016/j.coemr.2023.100448Thurston R.C. Symptom reporting, cardiovascular disease, and mortality as women age: it is more than menopause. Menopause. 2022;29(12):1355–1356. DOI: 10.1097/GME.0000000000002121Thurston R.C. Symptom reporting, cardiovascular disease, and mortality as women age: it is more than menopause. Menopause. 2022;29(12):1355–1356. DOI: 10.1097/GME.0000000000002121Юренева С.В., Аверкова В.Г. Вазомоторные симптомы в менопаузе: центральные триггеры, эффекторы и новые возможности патогенетической терапии. Российский вестник акушера-гинеколога 2018;5:43–48. DOI: 10.17116/rosakush20181805143Yureneva S.V., Averkova V.G. Menopausal vasomotor symptoms: central triggers, effectors, and new possibilities of pathogenetic therapy. Russian Bulletin of Obstetrician-Gynecologist. 2018;5:43–48. (in Russian). DOI: 10.17116/rosakush20181805143Nappi R.E., Siddiqui E., Todorova L. et al Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional survey Maturitas. 2023;167:66–74. doi: 10.1016/j.maturitas.2022.09.006Nappi R.E., Siddiqui E., Todorova L. et al Prevalence and quality-of-life burden of vasomotor symptoms associated with menopause: A European cross-sectional survey Maturitas. 2023;167:66–74. doi: 10.1016/j.maturitas.2022.09.006Miller V.M., Kling J.M., Files J.A. et al. What’s in a name: are menopausal ‘‘hot flashes’’ a symptom of menopause or a manifestation of neurovascular dysregulation? Menopause. 2018;25(6):700–703. DOI: 10.1097/GME.000000000000106Miller V.M., Kling J.M., Files J.A. et al. What’s in a name: are menopausal ‘‘hot flashes’’ a symptom of menopause or a manifestation of neurovascular dysregulation? Menopause. 2018;25(6):700–703. DOI: 10.1097/GME.000000000000106Thurston R.C., Carroll J.E., Levine M. et al. Vasomotor symptoms and accelerated epigenetic aging in the Women's Health Initiative (WHI). J. Clin. Endocrinol. Metab. 2020;105(4):1221–1227. DOI: 10.1210/clinem/dgaa081Thurston R.C., Carroll J.E., Levine M. et al. Vasomotor symptoms and accelerated epigenetic aging in the Women's Health Initiative (WHI). J. Clin. Endocrinol. Metab. 2020;105(4):1221–1227. DOI: 10.1210/clinem/dgaa081Armeni A., Anagnostis P., Armeni E. et al. Vasomotor symptoms and risk of cardiovascular disease in peri- and postmenopausal women : A systematic review and meta-analysis. Maturitas. 2023;171:13–20. DOI: 10.1016/j.maturitas.2023.02.004Armeni A., Anagnostis P., Armeni E. et al. Vasomotor symptoms and risk of cardiovascular disease in peri- and postmenopausal women : A systematic review and meta-analysis. Maturitas. 2023;171:13–20. DOI: 10.1016/j.maturitas.2023.02.004Muka T., Oliver-Williams C., Colpani V. et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease : a systematic review and meta-analysis. PLoS One. 2016;11:e0157417. DOI: 10.1371/journal.pone.0157417Muka T., Oliver-Williams C., Colpani V. et al. Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease : a systematic review and meta-analysis. PLoS One. 2016;11:e0157417. DOI: 10.1371/journal.pone.0157417Vogel B., Acevedo M., Appelman Y. et al. The Lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet. 2021;397(10292):2385–2438. DOI: 10.1016/S0140-6736(21)00684-XVogel B., Acevedo M., Appelman Y. et al. The Lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet. 2021;397(10292):2385–2438. DOI: 10.1016/S0140-6736(21)00684-XNewson L. Menopause and cardiovascular disease. Post. Reprod. Health. 2018;24(1):44–49. DOI: 10.1177/2053369117749675Newson L. Menopause and cardiovascular disease. Post. Reprod. Health. 2018;24(1):44–49. DOI: 10.1177/2053369117749675Samargandy S., Matthews K.A., Brooks M.M. et al. Trajectories of blood pressure in midlife women: does menopause matter? Circ. Res. 2022;130:312–322. DOI: 10.1161/CIRCRESAHA.121.319424Samargandy S., Matthews K.A., Brooks M.M. et al. Trajectories of blood pressure in midlife women: does menopause matter? Circ. Res. 2022;130:312–322. DOI: 10.1161/CIRCRESAHA.121.319424Cifkova R., Pitha J., Krajcoviechova A., Kralikova E. Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. Int. J. Cardiol. 2019;286:214–219. DOI: 10.1016/j.ijcard.2019.01.039Cifkova R., Pitha J., Krajcoviechova A., Kralikova E. Is the impact of conventional risk factors the same in men and women? Plea for a more gender-specific approach. Int. J. Cardiol. 2019;286:214–219. DOI: 10.1016/j.ijcard.2019.01.039D'Ignazio T., Grand'Maison S., Bérubé L. et al. Hypertension across a woman's lifespan. Maturitas. 2023;168:84–91. doi: 10.1016/j.maturitas.2022.11.006D'Ignazio T., Grand'Maison S., Bérubé L. et al. Hypertension across a woman's lifespan. Maturitas. 2023;168:84–91. doi: 10.1016/j.maturitas.2022.11.006Samargandy S., Matthews K.A., Brooks M.M. et al. Arterial stiffness accelerates within 1 year of the final menstrual period: the SWAN Heart Study. Arterioscler. Thromb. Vasc. Biol. 2020;40:1001–1008. DOI: 10.1161/ATVBAHA.119.313622Samargandy S., Matthews K.A., Brooks M.M. et al. Arterial stiffness accelerates within 1 year of the final menstrual period: the SWAN Heart Study. Arterioscler. Thromb. Vasc. Biol. 2020;40:1001–1008. DOI: 10.1161/ATVBAHA.119.313622Hildreth K.L., Ozeme C., Kohrt W.M. et al. Vascular dysfunction across the stages of the menopausal transition is associated with menopausal symptoms and quality of life. Menopause. 2018;25(9):1011–1019. DOI: 10.1097/GME.0000000000001112Hildreth K.L., Ozeme C., Kohrt W.M. et al. Vascular dysfunction across the stages of the menopausal transition is associated with menopausal symptoms and quality of life. Menopause. 2018;25(9):1011–1019. DOI: 10.1097/GME.0000000000001112Thurston R.C., Karvonen-Gutierrez C.A., Derby C.A. et al. Menopause versus chronologic aging: their roles in women’s health. Menopause. 2018;25:849–854. DOI: 10.1097/GME.0000000000001143Thurston R.C., Karvonen-Gutierrez C.A., Derby C.A. et al. Menopause versus chronologic aging: their roles in women’s health. Menopause. 2018;25:849–854. DOI: 10.1097/GME.0000000000001143Ding M., Manson J.E. HDL-C and arterial calcification in midlife women: does an HDL paradox exist? Menopause. 2021;28(3):231–233. DOI: 10.1097/GME.0000000000001734Ding M., Manson J.E. HDL-C and arterial calcification in midlife women: does an HDL paradox exist? Menopause. 2021;28(3):231–233. DOI: 10.1097/GME.0000000000001734Kronenberg F., Mora S., Stroes E.S.G. et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur. Heart J. 2022;43(39):3925–3946. DOI: 10.1093/eurheartj/ehac361Kronenberg F., Mora S., Stroes E.S.G. et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur. Heart J. 2022;43(39):3925–3946. DOI: 10.1093/eurheartj/ehac361Roa-Díaz Z.M., Wehrli F., Lambrinoudaki I. et al. Early menopause and cardiovascular risk factors: a cross-sectional and longitudinal study. Menopause. 2023;30(6): 599–606. DOI: 10.1097/GME.0000000000002184Roa-Díaz Z.M., Wehrli F., Lambrinoudaki I. et al. Early menopause and cardiovascular risk factors: a cross-sectional and longitudinal study. Menopause. 2023;30(6): 599–606. DOI: 10.1097/GME.0000000000002184Kase N.G., Friedman E.G., Brodman M. et al. The midlife transition and the risk of cardiovascular disease and cancer. Part I: magnitude and mechanisms. Am. J. Obstet. Gynecol. 2020;223(6):820–833. doi: 10.1016/j.ajog.2020.05.051Kase N.G., Friedman E.G., Brodman M. et al. The midlife transition and the risk of cardiovascular disease and cancer. Part I: magnitude and mechanisms. Am. J. Obstet. Gynecol. 2020;223(6):820–833. doi: 10.1016/j.ajog.2020.05.051Slopien R., Wender-Ozegowska E., Rogowicz-Frontczak A. et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6–10. DOI: 10.1016/j.maturitas.2018.08.009Slopien R., Wender-Ozegowska E., Rogowicz-Frontczak A. et al. Menopause and diabetes: EMAS clinical guide. Maturitas. 2018;117:6–10. DOI: 10.1016/j.maturitas.2018.08.009Woodward M., Peters S.A.E., Huxley R.R. Diabetes and the female disadvantage. Womens Health (Lond.). 2015;11(6):833–839. DOI: 10.2217/whe.15.67Woodward M., Peters S.A.E., Huxley R.R. Diabetes and the female disadvantage. Womens Health (Lond.). 2015;11(6):833–839. DOI: 10.2217/whe.15.67Banack H.R., Wactawski-Wende J., Hovey K.M., Stokes A. Is BMI a valid measure of obesity in postmenopausal women? Menopause. 2018;25:307–313. DOI: 10.1097/GME.0000000000000989Banack H.R., Wactawski-Wende J., Hovey K.M., Stokes A. Is BMI a valid measure of obesity in postmenopausal women? Menopause. 2018;25:307–313. DOI: 10.1097/GME.0000000000000989Wong J.C.H., O’Neill S., Beck B.R. et al. A 5-year longitudinal study of changes in body composition in women in the perimenopause and beyond. Maturitas. 2020;132:49–56. DOI: 10.1016/j.maturitas.2019.12.001Wong J.C.H., O’Neill S., Beck B.R. et al. A 5-year longitudinal study of changes in body composition in women in the perimenopause and beyond. Maturitas. 2020;132:49–56. DOI: 10.1016/j.maturitas.2019.12.001Greendale G.A., Sternfeld B., Huang M. et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4:e124865. DOI: 10.1172/jci.insight.124865Greendale G.A., Sternfeld B., Huang M. et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4:e124865. DOI: 10.1172/jci.insight.124865Ueda Y., Shiga Y., Idemoto Y. et al. Association between the presence or severity of coronary artery disease and pericardial fat, paracardial fat, epicardial fat, visceral fat, and subcutaneous fat as assessed by multi-detector row computed tomography. Int. Heart J. 2018;59(4):695–704. DOI: 10.1536/ihj.17-234Ueda Y., Shiga Y., Idemoto Y. et al. Association between the presence or severity of coronary artery disease and pericardial fat, paracardial fat, epicardial fat, visceral fat, and subcutaneous fat as assessed by multi-detector row computed tomography. Int. Heart J. 2018;59(4):695–704. DOI: 10.1536/ihj.17-234Laine C., Wee C.C. Overweight and obesity: current clinical challenges. Ann. Intern. Med. 2023;176(5):699–700. DOI: 10.7326/M23-0628Laine C., Wee C.C. Overweight and obesity: current clinical challenges. Ann. Intern. Med. 2023;176(5):699–700. DOI: 10.7326/M23-0628Ross R., Neeland I.J., Yamashita S. et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat. Rev. Endocrinol. 2020;16:177–189. DOI: 10.1038/s41574-019-0310-7Ross R., Neeland I.J., Yamashita S. et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. Nat. Rev. Endocrinol. 2020;16:177–189. DOI: 10.1038/s41574-019-0310-7Юренева С.В., Комедина В.И., Кузнецов С.Ю. Диагностические возможности антропометрических показателей для оценки ожирения у женщин в период менопаузального перехода. Акушерство и гинекология. 2022;(2):72–79. DOI: 10.18565/aig.2022.2.72-79Yureneva S.V., Komedina V.I., Kuznetsov S.Yu. Diagnostic value of anthropometric characteristics of obesity in women during the menopause transition. Obstetrics and Gynecology. 2022;(2):72–79. DOI: 10.18565/aig.2022.2.72-79Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women — 2011 update: a guideline from the American Heart Association. Circulation 2011;123: 1243–1262. DOI: 10.1161/CIR.0b013e31820faaf8Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women — 2011 update: a guideline from the American Heart Association. Circulation 2011;123: 1243–1262. DOI: 10.1161/CIR.0b013e31820faaf8Lloyd-Jones D.M., Allen N.B., Anderson C.A.M. et al. Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory from the American Heart Association. Circulation. 2022;146(5):18–43. DOI: 10.1161/CIR.0000000000001078Lloyd-Jones D.M., Allen N.B., Anderson C.A.M. et al. Life’s Essential 8: Updating and Enhancing the American Heart Association’s Construct of Cardiovascular Health: A Presidential Advisory from the American Heart Association. Circulation. 2022;146(5):18–43. DOI: 10.1161/CIR.0000000000001078Zhou T., Yuan Y., Xue Q. et al. Adherence to a healthy sleep pattern is associated with lower risks of all-cause, cardiovascular and cancer-specific mortality. J. Intern. Med. 2021;291(1):64–71. DOI: 10.1111/joim.13367Zhou T., Yuan Y., Xue Q. et al. Adherence to a healthy sleep pattern is associated with lower risks of all-cause, cardiovascular and cancer-specific mortality. J. Intern. Med. 2021;291(1):64–71. DOI: 10.1111/joim.13367Grundy S.M., Stone N.J., Bailey A.L. et al. 2018 guideline on the management of blood cholesterol: a report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1182–1186]. Circulation 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625Grundy S.M., Stone N.J., Bailey A.L. et al. 2018 guideline on the management of blood cholesterol: a report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139:e1182–1186]. Circulation 2019;139:e1082–e1143. DOI: 10.1161/CIR.0000000000000625DePree B., Houghton K., Shiozawa A. et al. Treatment and resource utilization for menopausal symptoms in the United States : a retrospective review of real-world evidence from US electronic health records. Menopause. 2023;30(1):70–79. DOI: 10.1097/GME.0000000000002095DePree B., Houghton K., Shiozawa A. et al. Treatment and resource utilization for menopausal symptoms in the United States : a retrospective review of real-world evidence from US electronic health records. Menopause. 2023;30(1):70–79. DOI: 10.1097/GME.0000000000002095Cho L., Kaunitz A.M., Faubion S.S. et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? Circulation. 2023;147:597–610. DOI: 10.1161/CIRCULATIONAHA.122.061559Cho L., Kaunitz A.M., Faubion S.S. et al. Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long? Circulation. 2023;147:597–610. DOI: 10.1161/CIRCULATIONAHA.122.061559Mehta J., Kling J.M., Manson J.E. Risks, benefits, and treatment modalities of menopausal hormone therapy: current concepts. Front. Endocrinol. (Lausanne) 2021:12:564781. DOI: 10.3389/fendo.2021.564781Mehta J., Kling J.M., Manson J.E. Risks, benefits, and treatment modalities of menopausal hormone therapy: current concepts. Front. Endocrinol. (Lausanne) 2021:12:564781. DOI: 10.3389/fendo.2021.564781Manson J.E., Aragaki A.K., Rossouw J.E. et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318:927–938. DOI: 10.1001/jama.2017.11217Manson J.E., Aragaki A.K., Rossouw J.E. et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. JAMA. 2017;318:927–938. DOI: 10.1001/jama.2017.11217Miller V.M., Naftolin F., Asthana S. et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019;26(9):1071–1084. DOI: 10.1097/GME.0000000000001326Miller V.M., Naftolin F., Asthana S. et al. The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned? Menopause. 2019;26(9):1071–1084. DOI: 10.1097/GME.0000000000001326Hodis H.N., Mack W.J., Henderson V.W. et al; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N. Engl. J. Med. 2016;374(13):1221–1231. DOI: 10.1056/NEJMoa1505241Hodis H.N., Mack W.J., Henderson V.W. et al; ELITE Research Group. Vascular effects of early versus late postmenopausal treatment with estradiol. N. Engl. J. Med. 2016;374(13):1221–1231. DOI: 10.1056/NEJMoa1505241El Khoudary S.R., Zhao Q., Venugopal V. et al. Effects of hormone therapy on heart fat and coronary artery calcification progression: secondary analysis from the KEEPS trial. J. Am. Heart Assoc. 2019;8:e012763. DOI: 10.1161/JAHA.119.012763115El Khoudary S.R., Zhao Q., Venugopal V. et al. Effects of hormone therapy on heart fat and coronary artery calcification progression: secondary analysis from the KEEPS trial. J. Am. Heart Assoc. 2019;8:e012763. DOI: 10.1161/JAHA.119.012763115Faubion S.S., Crandall C.J., Davis L. et al. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. DOI: 10.1097/GME.0000000000002028Faubion S.S., Crandall C.J., Davis L. et al. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. DOI: 10.1097/GME.0000000000002028El Khoudary S.R., Venugopal V., Manson J.E. et al. Heart fat and carotid artery atherosclerosis progression in recently menopausal women: impact of menopausal hormone therapy: the KEEPS trial. Menopause. 2020;27:255–262. DOI: 10.1097/GME.0000000000001472El Khoudary S.R., Venugopal V., Manson J.E. et al. Heart fat and carotid artery atherosclerosis progression in recently menopausal women: impact of menopausal hormone therapy: the KEEPS trial. Menopause. 2020;27:255–262. DOI: 10.1097/GME.0000000000001472Gambacciani M., Cagnacci A., Lello S. Hormone replacement therapy and prevention of chronic conditions. Climacteric. 2019;22(3):303–306. DOI: 10.1080/13697137.2018.1551347Gambacciani M., Cagnacci A., Lello S. Hormone replacement therapy and prevention of chronic conditions. Climacteric. 2019;22(3):303–306. DOI: 10.1080/13697137.2018.1551347Dinger J., Bardenheuer K., Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016;19(4):349–356. DOI: 10.1080/13697137.2016.1183624Dinger J., Bardenheuer K., Heinemann K. Drospirenone plus estradiol and the risk of serious cardiovascular events in postmenopausal women. Climacteric. 2016;19(4):349–356. DOI: 10.1080/13697137.2016.1183624

The authors declare that there are no conflicts of interest present.